SS-31 keeps coming up in longevity and energy conversations, usually framed as the peptide that fixes your mitochondria. The mechanism behind that framing is real and genuinely interesting. The trial record, though, is a mixed bag that most discussions gloss over, some clear wins, some notable misses. Here is the honest full breakdown: what it is, how it works, what the trials actually found, how it's dosed, and where it realistically fits.
What is SS-31?
SS-31, also called elamipretide, is a small four-amino-acid peptide (a tetrapeptide) designed to do one specific thing: get inside the mitochondria and target the part that is failing. Most compounds cannot selectively reach the inner mitochondrial membrane; SS-31 is built to, which is what separates it from the general "energy support" supplements it often gets compared to. It crossed a real regulatory milestone recently: it received FDA accelerated approval as the first treatment for Barth syndrome, a rare genetic mitochondrial disorder.
How it works
Mitochondria are the cell's power plants, and the inner membrane is where the actual energy (ATP) gets produced. A specific fat in that membrane called cardiolipin keeps the energy-production machinery organized and running efficiently. As cells age or come under stress, that machinery gets disorganized, output drops, and the production of damaging byproducts (reactive oxygen species, the source of oxidative stress) rises. SS-31 binds to cardiolipin and stabilizes the structure, which does three things at once: cleaner electron transport, less oxidative waste, and more ATP from tissues that burn a lot of energy. The appeal is that it is not adding fuel; it is repairing the machine that makes the fuel, which is why it draws so much interest in mitochondrial, muscle, heart, and brain contexts.
The evidence
This is the part that needs the honest version. The mechanism is well-established, and the safety record in trials has been clean, no dose-limiting toxicities and no serious adverse events attributed to it. But the efficacy results are genuinely mixed. The Phase 2 trials in heart failure and in primary mitochondrial myopathy did not meet their primary endpoints. What did succeed was the Barth syndrome program, where SS-31 produced real improvements in muscle strength and walking distance, and that is what earned the FDA accelerated approval.
So the fair read is layered: proven for one rare genetic condition, strong and well-described on mechanism, but the broader "anti-aging energy" use that drives most of the hype still rests largely on preclinical models rather than human wins. Anyone selling SS-31 as a sure thing for general energy or longevity is ahead of the data. The honest position is a compelling mechanism with a real but narrow approval and an incomplete human-outcomes record.
Dosing (research reference)
For a reconstitution reference, a 10 mg vial with 1 mL of bacteriostatic water gives 10 mg/mL, where 1 unit on a U-100 syringe is 100 mcg.
A standard reference protocol runs a short titration: about 5 mg daily (roughly 50 units) for the first two weeks, then 10 mg daily (roughly 100 units) for weeks 3 through 8, injected once daily subcutaneously at a consistent time. There is also an advanced reference range of 15 to 20 mg daily that derives from short-term clinical protocols for severe mitochondrial disease; at those higher doses it is split into two separate injections. Worth knowing: the trials mostly did not run past about 12 weeks, so anything longer than that is beyond where the data exists.
Side effects
SS-31 is one of the better-tolerated peptides on the systemic side, it did not meaningfully move blood pressure, heart rate, or standard labs in trials. The one common effect is local: injection-site reactions (redness, itching, mild discomfort) were reported in a large share of trial participants, but they are mild and usually resolve within hours. The genuine gap is long-term safety, since there is little data beyond roughly 12 weeks, so extended use is uncharted territory rather than a known quantity.
Storage
Lyophilized SS-31 is kept frozen, sealed and out of light, for longer storage. Once reconstituted it is refrigerated at 2 to 8 degrees C and used within about four weeks, with no refreezing. Letting a refrigerated vial reach room temperature before opening reduces condensation.
Where it fits
SS-31 is one of the more scientifically legitimate peptides in the longevity space, the cardiolipin mechanism is real, the safety looks solid, and it cleared the bar for an actual FDA approval. But that approval is specifically for a rare genetic disease, not the general energy and anti-aging use most people are chasing, and two of its larger trials missed their endpoints. The accurate framing is a compound with a strong mechanism and an honest, still-incomplete evidence trail, not the proven longevity tool it sometimes gets sold as. For anyone exploring it, the basic mitochondrial-support fundamentals (sleep, training, and the nutrients that support the same machinery) are doing more of the work than they usually get credit for.